Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

Cardiovascular Diabetology

Original Investigation

Ole P. Kristiansen¹  Preman Kumarathurai¹  Ahmad Sajadieh¹  Olav W. Nielsen¹  Sten Madsbad²  Jens Mølvig³  Christian Anholm³  Steen B. Haugaard⁴ 

[1] Department of Cardiology, Copenhagen University Hospital of Bispebjerg, Bispebjerg Bakke 23, 2400, Copenhagen, Denmark;Department of Endocrinology, Copenhagen University Hospital of Hvidovre, Copenhagen, Denmark;Department of Internal Medicine, Copenhagen University Hospital of Amager, Copenhagen, Denmark;Department of Internal Medicine, Copenhagen University Hospital of Amager, Copenhagen, Denmark;Clinical Research Center, Copenhagen University Hospital of Hvidovre, Copenhagen, Denmark;

关键词: GLP-1;    Liraglutide;    Coronary artery disease;    Diabetes mellitus;    Dobutamine stress echocardiography;    Left ventricular ejection fraction;   

DOI  :  10.1186/s12933-016-0425-2

 received in 2016-06-01, accepted in 2016-07-19,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundPatients with type 2 diabetes (T2D) and coronary artery disease (CAD) have increased risk of cardiac dysfunction. The diabetic heart is characterized by increased fatty acid oxidation and reduced glucose uptake resulting in reduced cardiac efficiency. Glucagon-like peptide-1 (GLP-1) has shown to increase myocardial glucose uptake and to improve myocardial function. We examined the effect of the GLP-1 receptor agonist, liraglutide, on the systolic function of the left ventricle (LV) in patients with T2D and stable CAD.MethodsIn this placebo-controlled crossover study, 41 subjects with T2D and stable CAD were randomized to liraglutide or placebo and underwent dobutamine stress echocardiography (DSE) and exercise tolerance test at beginning and end of each intervention. The primary endpoint was changes in LV ejection fraction. Secondary endpoints were exercise capacity and other measures of systolic function: wall motion score index (WMSI), global longitudinal strain (GLS) and strain rate (GLSR).ResultsLiraglutide, when compared to placebo, did not improve LV ejection fraction at rest (+0.54 %; 95 % CI 2.38–3.45), at low stress (+0.03 %; 95 % CI 3.25–3.32), at peak stress (+1.12 %; 95 % CI 3.45–5.69), or at recovery (+4.06 %; 95 % CI 0.81–8.93). No significant changes in WMSI were observed at any stress levels. GLS and GLSR at rest did not improve. The maximal exercise capacity estimated by metabolic equivalents was not affected by liraglutide.ConclusionIn conclusion, liraglutide did not improve the systolic function of the left ventricle during DSE or the exercise capacity in patients with T2D and stable CAD.Clinical Trial Registrationhttp://www.clinicaltrials.gov (unique identifier: NCT01595789)

【 授权许可】

CC BY   
© The Author(s) 2016